FDA Clearance to Treat Keloids with the SRT-100

Sensus Healthcare officials announce that it has received clearance from the U.S. Food and Drug Administration to treat Keloids with the SRT-100.

The SRT-100 is the leading alternative to surgery in treating Non Melanoma Skin Cancer and now is approved to treat Keloids caused by surgery or injury. Leading Dermatologists and Oncologists have found the SRT-100 superficial radiotherapy system to be an excellent choice for their patients who are not good surgical candidates. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers and keloids in hospitals and private practice settings.

“Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45% to 100%. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences,” stated Mark S. Nestor, MD, PhD of the Center for Cosmetic Enhancement in Aventura, FL.

Dr. Nestor continues to say, “It is very fortunate that the FDA has approved the Sensus SRT-100, the first computerized, state of the art in office SRT device, for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in office modality available to offer our keloid patients.”

“The SRT-100 technology continues to demonstrate its potential as we expand our indications into other areas of treatment. This important indication can be applied to every surgical procedure for those patients susceptible to forming keloids,” states Joe Sardano, president/CEO, Sensus Healthcare.

SRT-100 is an ideal treatment modality for non-melanoma skin cancers and keloids, thanks to its SharpBeam technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.